AOH1996
| AOH1996 |
|---|
| instantia de: typo de entitate chimic[*] |
| subclasse de: composito chimic |
|
|
AOH1996 es un chimiotherapia experimental anticancere. Iste molecula inhibi un forma particular del antigene nuclear del cellulas proliferante (en) (PCNA), qui es specific al cellulas canceree.[1][2][3][4]
Le proteina PCNA es crucial pro reparar le ADN de omne cellulas. Le tractamento presenta le interesse de affectar solmente cellulas tumoral.[5] Poterea ager contra canceres del pectore, prostata, cerebro, ovarios, collo uterin, pelle e pulmon.[6][7]
Su nomine es un hominaje a Anna Olivia Healy, un filia de 9 annos morte in 2006 de consequentias de un neuroblastoma. Le fundos colligite per su parentes ha adjutate a disveloppar iste medicamento.[6][8]
Referentias
- ↑ Malkas LH, et al. PCNA Inhibitors. Patent WO 2017/049206
- ↑ “Arginine shortage induces replication stress and confers genotoxic resistance by inhibiting histone H4 translation and promoting PCNA ubiquitination” (1 de martio 2023). Cell Reports 42 (4): 112296. PMID: 36961817.
- ↑ “Small molecule targeting of transcription-replication conflict for selective chemotherapy” (1 de augusto 2023). Cell Chemical Biology. doi:.
- ↑ AOH1996 for the Treatment of Refractory Solid Tumors.
- ↑ “The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA” (1 de decembre 2018). Clinical Cancer Research 24 (23): 6053–6065. PMID: 29967249.
- 1 2 Anna (9) starb an Krebs – jetzt ist die Wunderpille nach ihr benannt [Anna (9) died of cancer - now the miracle pill is named after her] (in germano). 20 Minuten (2 de augusto 2023).
- ↑ 'Cancer-killing pill' that appears to 'annihilate' solid tumours is now being tested on humans (in anglese).
- ↑ AOH-1996 Is Here!. ANNA Fund (21 de decembre 2021).